Company intelligence / Profile preview

Amsel Medical

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

SCureClamp™ with iDOT™ demonstrated secure, permanent vessel occlusion comparable to transfixion sutures in preclinical studies, with successful deployment in vascular and laparoscopic models. SCureTO™ offers minimally invasive, adjustable, and removable occlusion for hemorrhage control, targeting military/civilian trauma settings and received a $7.45M USAF contract for commercialization.

Therapeutic areas: CardiovascularHematologyOther
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

United States Air Force (USAF)Department of Defense (DoD)

Beyond the preview

Go deeper on Amsel Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amsel Medical.

Explore the full profile